semaglutide news october 26 2025 In the original clinical trials looking at (the GLP-1 in Novo Nordisk's Ozempic and Wegovy) and tirzepatide (in Eli Lilly's Mounjaro and Zepbound), patients gained back most of the weight after Semaglutide lowers cardiovascular events even

Rybelsus is an oral GLP-1 receptor agonist licensed in the UK for type 2 diabetes treatment in adults

The study suggests that over a two-year period, Ozempic reduces major cardiovascular events like heart attacks but doesnt reduce the risk of dying of cardiovascular disease during this time

What is the Medicare GLP-1 Bridge program and how does it work

dose that was used for the cardiovascular study

For optimal weight loss outcomes with Rybelsus, it is essential to follow a calorie-controlled diet, maintain regular physical activity, and prioritise healthy habits such as stress management and sufficient sleep

NovoNordisks original formulation is a semaglutide base, not semaglutide salt